VU 0285683

Pricing Availability Delivery Time Qty
Cat.No. 4381 - VU 0285683 | C14H7FN4O | CAS No. 327056-22-4
Description: Negative allosteric modulator at mGlu5
Chemical Name: 3-Fluoro-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-benzonitrile
Purity: ≥98% (HPLC)
Datasheet
Citations
Literature

Biological Activity

Negative allosteric modulator of mGlu5 receptors. Displays high affinity for the MPEP (Cat. No. 1212) binding site; acts as a full antagonist and blocks the glutamate response to mGlu5 (IC50 = 24.4 nM). Selective for mGlu5 over mGlu1, mGlu3 and mGlu4. Exhibits anxiolytic activity in rodent models of anxiety. Analog available (Cat. No. 4323).

Technical Data

M. Wt 266.23
Formula C14H7FN4O
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 327056-22-4
PubChem ID 9816778
InChI Key GELAFISMURFRCA-UHFFFAOYSA-N
Smiles FC1=CC(C#N)=CC(C2=NC(C3=NC=CC=C3)=NO2)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 13.31 50
ethanol 6.66 25

Preparing Stock Solutions

The following data is based on the product molecular weight 266.23. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.76 mL 18.78 mL 37.56 mL
5 mM 0.75 mL 3.76 mL 7.51 mL
10 mM 0.38 mL 1.88 mL 3.76 mL
50 mM 0.08 mL 0.38 mL 0.75 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Rodriguez (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol.Pharmacol. 78 1105 PMID: 20923853


If you know of a relevant reference for VU 0285683, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Modulators

Keywords: Negative allosteric modulators mGlu5 mGluR5 mGlur Group I Receptors Glutamate Metabotropic MPEP binding site VU0285683 nams Glutamate (Metabotropic) Group I Receptors

Citations for VU 0285683

Citations are publications that use Tocris products.

Currently there are no citations for VU 0285683. Do you know of a great paper that uses VU 0285683 from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Metabotropic Glutamate Receptors

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease

Huntington's Disease Poster

Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Pathways for VU 0285683

Protocols

TODO: Add Protocols